BOSTON and BORDEAUX, France, April 23, 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D).

波士顿和波尔多，法国，2024年4月23日/PRNewswire/--Vertex Pharmaceuticals Incorporated（纳斯达克：VRTX）和TreeFrog Therapeutics今天宣布，Vertex已获得TreeFrog专有细胞制造技术C-StemTM的独家许可，以优化Vertex针对1型糖尿病（T1D）的细胞疗法的生产。

TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies..

TreeFrog和Vertex将合作扩大TreeFrog生产和扩增Vertex T1D治疗细胞的过程。。

TreeFrog's proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.

TreeFrog的专有技术平台C-Stem™旨在模拟自然微环境，使细胞在3D中呈指数增长。该技术将增强Vertex为其T1D细胞疗法组合产生大量完全分化细胞的能力。

'Our goal is to transform the treatment of T1D, and our stem cell-derived, fully differentiated islet cell VX-880 Ph 1/2 program has demonstrated this potential,' said Morrey Atkinson Ph.D., Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, at Vertex.

Vertex执行副总裁、首席技术运营官、生物制药科学和制造运营负责人莫雷·阿特金森博士说：“我们的目标是改变T1D的治疗方式，我们的干细胞衍生的完全分化胰岛细胞VX-880 Ph 1/2计划已经证明了这一潜力。”。

'We're excited to explore TreeFrog's C-StemTM to scale up stem cell production and deliver for the large number of people living with T1D.'.

“我们很高兴探索TreeFrog的C-StemTM，以扩大干细胞生产并为大量T1D患者提供。”。

'We are delighted to partner with Vertex Pharmaceuticals, the clear leader in cell therapy for T1D. This is a fantastic opportunity to apply and further develop our C-Stem™ technology for a first-in-class cell therapy treatment which could meet a huge unmet need,' said Frédéric Desdouits, Ph.D., CEO of TreeFrog Therapeutics.

“我们很高兴与Vertex Pharmaceuticals合作，Vertex Pharmaceuticals是T1D细胞治疗领域的明确领导者。TreeFrog Therapeutics首席执行官Frédéric Desdouits博士说，这是一个绝佳的机会，可以应用和进一步开发我们的C-Stem™技术，用于一流的细胞治疗，可以满足巨大的未满足需求。

'This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners like Vertex. We look forward to combining TreeFrog's extensive experience in cell therapy production and biology with Vertex's renowned expertise in T1D and cell therapy to bring these transformative therapies to patients.'.

“与Vertex的合作推进了我们的商业战略，通过我们自己的治疗计划以及Vertex等一流合作伙伴，帮助数百万人获得一流的细胞疗法。我们期待着将TreeFrog在细胞疗法生产和生物学方面的丰富经验与Vertex在T1D和细胞疗法方面的著名专业知识相结合，为患者带来这些变革性疗法。”。

About the Transaction

关于交易

Under the agreement, TreeFrog will receive a $25M upfront payment, an equity investment from Vertex and up to $215M in milestones paid in connection with the development of a scaled-up process for fully differentiated islet cells. TreeFrog is also eligible to receive an additional $540M in clinical, regulatory and commercial milestones on up to two future products and tiered single digit royalties.

根据该协议，TreeFrog将获得2500万美元的预付款，Vertex的股权投资，以及高达2.15亿美元的里程碑，用于开发完全分化的胰岛细胞的放大过程。TreeFrog还有资格获得另外5.4亿美元的临床、监管和商业里程碑，用于未来最多两种产品和分层的单位数字版税。

Vertex will fund all research and development costs related to the collaboration. Vertex will be responsible for all development and commercialization of its cell therapies..

Vertex将资助与合作相关的所有研发成本。Vertex将负责其细胞疗法的所有开发和商业化。。

About Vertex

关于顶点

Visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

Visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

About TreeFrog Therapeutics

关于TreeFrog Therapeutics

TreeFrog Therapeutics is a French-based biotech company set to unlock access to cell therapies for millions of patients.

TreeFrog Therapeutics是一家总部位于法国的生物技术公司，旨在为数百万患者提供细胞疗法。